Impact of 21st Century Cures Act on Breakpoints and Commercial Antimicrobial Susceptibility Test Systems: Progress and Pitfalls

• Published in: Journal of clinical microbiology Vol. 56; no. 5
• Main Authors: Humphries, Romney M, Ferraro, Mary Jane, Hindler, Janet A
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.05.2018
• Subjects: Anti-Bacterial Agents - therapeutic use; Diagnostic Tests, Routine - methods; Diagnostic Tests, Routine - standards; Health Policy - history; Health Policy - legislation & jurisprudence; History, 21st Century; Humans; Microbial Sensitivity Tests - methods; Microbial Sensitivity Tests - standards; Minireview; United States; United States; 21st Century Cures Act; antimicrobial susceptibility testing; Clinical and Laboratory Standards Institute; breakpoints; Food and Drug Administration
• ISSN: 0095-1137; 1098-660X
• DOI: 10.1128/JCM.00139-18

Antimicrobial resistance is the most pressing medical challenge of the past decade. At the front line are clinical laboratories, which are responsible for accurately reporting antimicrobial susceptibility test (AST) results to clinicians and public health authorities. The ability of the laboratory to detect resistance has been hampered by several factors. In 2016, the 21st Century Cures Act was signed into law, marking an important step toward resolving many regulatory dilemmas that hampered development and updates to commercial AST systems (cASTs). We describe the pathway and history of U.S. regulation of cASTs and outline both the rewards and unmet needs possible from the 21st Century Cures Act.